论文部分内容阅读
Objective:To evaluate the toxicity of paclitaxel and cisplatin combination in patients with advanced ovarian cancer.Methods:A retrospective review was performed on patients with stage Ⅲ or stage Ⅳ ovarian cancer treated in QiLu hospital between October 1996 and June 1999 Results:26 patients received adjuvant paclitaxel and cisplatin chemotherapy.The significant toxicity included:anemia 7/26(27%),thrombocytopenia 10/26(38%),neutropenia 19/26(73%),nausea or vomiting 24/26(92%) and neurotoxicity 11/26(42%).No patient delayed.No patient died during treatment.Conclusion:The dosages of primary paclitaxel and cisplatin chemotherapy is reasonably well tolerated for patients with stage Ⅲ or Ⅳ ovarian cancer.
Objective: To evaluate the toxicity of paclitaxel and cisplatin combination in patients with advanced ovarian cancer. Methods: A retrospective review performed of patients with stage Ⅲ or stage Ⅳ ovarian cancer treated in Qi Hospital between October 1996 and June 1999 Results: 26 patients received adjuvant paclitaxel and cisplatin chemotherapy. compromised included anemia 7/26 (27%), thrombocytopenia 10/26 (38%), neutropenia 19/26 (73%), nausea or vomiting 24/26 No patient delayed. No patient died during treatment. Confusion: The dosages of primary paclitaxel and cisplatin chemotherapy is reasonably well tolerated for patients with stage III or IV ovarian cancer.